Your new post is loading...
Available credits for clinical personel
Clinical Context
Human papillomavirus (HPV) is the most commonly detected sexually transmitted organism in women. It is responsible for cervical cancer in women, as well as other anogenital cancers and genital warts in both men and women. In June 2006, the US Food and Drug Administration approved the HPV vaccine for females aged 9 to 26 years for the prevention of cervical cancer. However, more recently, the recommendations for quadrivalent HPV vaccine was expanded to females aged 9 to 26 for prevention of vaginal and vulvar cancer, men aged 9 to 26 years for prevention of genital warts, and females and males aged 9 to 26 years old for prevention of anal intraepithelial neoplasia and anal cancer. The quadrivalent human papillomavirus vaccine has been known to be safe, well tolerated, and highly immunogenic.
The aim of this study by Klein and colleagues was to assess the safety of the quadrivalent HPV vaccine in females after routine administration.
